Sentences with phrase «myeloma patients»
The phrase "myeloma patients" refers to people who have a type of cancer called multiple myeloma. It is a disease that affects certain cells in the bone marrow, which can cause problems in the body's immune system and the production of blood cells. Full definition
Half of multiple myeloma patients diagnosed in the earliest stage of the disease don't survive beyond about five years after initial treatment because the cancer becomes resistant to treatments.
sciencedaily.com
The prognosis of myeloma patients with EMD behaves like other metastatic cancers and is extremely poor because its clinical course is very aggressive, Tse said.
Results from a clinical trial investigating a new T cell receptor (TCR) therapy that uses a person's own immune system to recognize and destroy cancer cells demonstrated a clinical response in 80 percent of multiple myeloma patients with advanced disease after undergoing autologous stem cell transplants (ASCT).
The MMRF's early investment in Selinexor yields promising results for myeloma patients Learn More
Using a database of multiple myeloma patient samples and information, researchers at University of California San Diego School of Medicine found that high ADAR1 levels correlate with reduced survival rates.
A multiple myeloma patient whose cancer had stopped responding after nine different treatment regimens experienced a complete remission after receiving an investigational personalized cellular therapy known as CTL019 developed by a team at the University of Pennsylvania.
To unravel exactly how ADAR1 is connected to disease severity at a molecular level, the researchers transferred multiple myeloma patient tissue to mice, creating what's known as a xenograft or «humanized» model.
Figure on the right: Bortezomib treatment is significantly less effective in multiple myeloma patients who have suppressed expression of a 19s proteasome cap subunit.
«If we could pharmacologically suppress these fatty acid levels in obese myeloma patients, we could boost the effects of the chemotherapy that targets PKA or fatty acid synthesis, and potentially decrease the chemotherapeutic dose,» Medina said.
The method relies on 3 - D tissue - engineered bone marrow (3DTEBM) cultures that Azab and his colleagues developed using myeloma patients» bone marrow samples.
«Multiple myeloma patient study shows promise for natural killer cells: Phase I study included combination with high - dose chemotherapy and stem cell transplantation.»
Initial treatment for most multiple myeloma patients includes a class of drugs (Revlimid or Pomalyst) broadly known as immune modulators.
A first - in - human Phase I study of multiple myeloma patients combined expanded cord blood - derived natural killer cells with transplantation of a patient's own stem cells and high - dose chemotherapy with little or none of the side effects seen with current treatments.
Nearly 80 % of R / R myeloma patients with severe renal impairment requiring hemodialysis achieved disease control with this treatment combination.
«In the past decade, new treatments for the disease have spurred a remarkable improvement in survival for myeloma patients, but those benefits have disproportionately increased survival rates for Caucasian patients,» Carpten said.
Analyzing a database of nearly 800 multiple myeloma patient samples, they discovered that 162 patients with low ADAR1 levels in their tumor cells survived significantly longer over a three - year period compared to 159 patients with high ADAR1 levels.
PHILADELPHIA — A multiple myeloma patient whose cancer had stopped responding after nine different treatment regimens experienced a complete remission after receiving an investigational personalized cellular therapy known as CTL019 developed by a team at the University of Pennsylvania.
Researchers used tissue and blood samples to show that the gammopathy (a precursor to myeloma) in both mice and patients with Gaucher disease is triggered by specific lipids, and that the antibodies made by tumor cells in nearly a third of myeloma patients are directed against such lipids.
The combination of pomalidomide plus low - dose dexamethasone showed efficacy with high rates of disease control in relapsed or refractory multiple myeloma patients with severe renal impairment, according to the results of a phase II study.
«Choice of medical center impacts life expectancy of multiple myeloma patients, study shows.»
Thirty to 50 percent of multiple myeloma patients have extra copies of the gene that encodes the enzyme ADAR1.
«Several major advances in recent years have been good news for multiple myeloma patients, but those new drugs only target terminally differentiated cancer cells and thus can only reduce the bulk of the tumor,» said Jamieson, who is also deputy director of the Sanford Stem Cell Clinical Center, director of the CIRM Alpha Stem Cell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego Health.
Furthermore, the levels of Runx2 expression among a larger group of 351 newly diagnosed multiple myeloma patients were significantly higher in patients who had a high risk of early disease - related death, as compared with lower - risk patients.
In humans, a comparison of bone marrow from 14 normal bone marrow donors, 35 multiple myeloma patients and 11 patients with a noncancerous condition called monoclonal gammopathy of undetermined significance (MGUS) showed that Runx2 levels were significantly higher in the multiple myeloma cells.
While some previous studies found that maintenance lenalidomide after autologous hematopoietic stem cell transplant improved overall survival for newly diagnosed multiple myeloma patients, others showed no benefit to this approach.
«African - American multiple myeloma patients have higher incidence rates and lower survival rates than their Caucasian peers despite this being a relatively easy - to - treat cancer.
For example, in the study, multiple myeloma patients of European descent were six times more likely than their African peers to have mutations in the TP53 gene, a tumor suppressor that helps prevent cancer.
Researchers analyzed the genetic sequencing data of 718 multiple myeloma patients and found that African - Americans had increased mutations in the genes BCL7A, BRWD3 and AUTS2, while white people had more mutations in the genes TP53 and IRF4.
Researchers at MIT have now shown that they can use a new type of measurement to predict how drugs will affect cancer cells taken from multiple - myeloma patients.
In the new study, the researchers teamed up with Nikhil Munshi at Dana - Farber Cancer Institute to test a variety of drugs on tumor cells from multiple - myeloma patients.
«Personalized drug screening on horizon for multiple myeloma patients.»
«The drug, LCL161, was initially developed to promote tumor death,» says Marta Chesi, Ph.D., a Mayo Clinic biochemist and lead author of the study of 25 Multiple Myeloma patients.
The new report expands on data that were presented during the American Society of Clinical Oncology meeting in June 2015 about the first five myeloma patients to receive CTL019, which was tested in trials for leukemia beginning in 2010.
However, since MGUS and SMM are both asymptomatic conditions, most myeloma patients are not diagnosed until organ damage occurs.
Dr Matt Kaiser, Head of Research at Bloodwise, said, «Myeloma is a devastating cancer that can cause debilitating and painful bone damage and, although we have become better at treating it and extending the lives of myeloma patients, it is ultimately almost always fatal.
The research team found over 200 products of metabolism differed between the healthy volunteers and patients with MGUS or myeloma, compared to just 26 differences between MGUS patients and myeloma patients.
Richard Vague, the event's honorary chair, took the podium to acknowledge the vast achievements of the ACC, as did Lori Alf, a multiple myeloma patient of Edward Stadtmauer, MD, chief of Hematologic Malignancies, whose cancer is in remission after receiving chimeric antigen receptor (CAR) therapy.
The current study, which has accrued 32 patients to date, is the first in - human study of daratumumab in multiple myeloma patients.
The only documented long - term complete remissions reported in multiple myeloma patients have occurred with allogeneic bone marrow transplantation, where a donor's blood stem cells (graft) are transplanted into the patient (host) with multiple myeloma.
This page features information on multiple myeloma and immunotherapy clinical trials for multiple myeloma patients, and highlights the Cancer Research Institute's role in working to bring effective immune - based cancer treatments to people with multiple myeloma.
Most multiple myeloma patients, however, are ineligible for allogeneic transplantation due to age and medical restrictions.
Innovative approaches to harness the immune system to fight multiple myeloma and stimulate a «host - vs - myeloma» effect will benefit the majority of myeloma patients.
December 6, 2011 Drug combination highly effective for newly diagnosed myeloma patients, study finds A three - drug combination treatment for the blood cancer multiple myeloma compares favorably to the best established therapy for newly diagnosed patients, according to a multi-center study led by Andrzej Jakubowiak, MD, PhD, professor of medicine and director of the multiple myeloma program at the University of Chicago Medical Center.
Darbepoietin - Alfa after High - Dose Melphalan and Autologous Hemopoietic Progenitor Cell in Multiple Myeloma Patients: A Pilot Study